Contact and support
Need help, have a question, or want to contact the ResearchHub team?
© 2026 ResearchHub. Built for responsible scholarly connection.
Privacy-aware community infrastructureResearch graph
References from Innovative liposomal amphotericin B formulation for oral treatment of visceral leishmaniasis. Local targets link to admitted publications; unresolved targets remain external evidence.
Development, characterization, efficacy and mode of action of Ambisome, a unilamellar liposomal formulation of amphotericin B
10.3109/08982109309150729 · 1993 · External reference
Experience of research nurses with oral encochleated amphotericin B for treatment of cryptococcal meningitis in a resource-limited setting
10.1186/s12879-025-11319-1 · 2025 · External reference
Mixed formulation of conventional and pegylated liposomes as a novel drug delivery strategy for improved treatment of visceral leishmaniasis
10.1517/17425247.2014.932347 · 2014 · External reference
Pharmacokinetics, excretion, and mass balance of liposomal amphotericin B (AmBisome) and amphotericin B deoxycholate in humans
10.1128/aac.46.3.828-833.2002 · 2002 · External reference
Natural resistance of Leishmania infantum to Miltefosine contributes to the low efficacy in the treatment of visceral Leishmaniasis in Brazil
10.4269/ajtmh.18-0949 · 2019 · External reference
In vivo antileishmanial activity and histopathological evaluation in Leishmania infantum infected hamsters after treatment with a furoxan derivative
10.1016/j.biopha.2017.08.096 · 2017 · External reference
Therapeutic efficacy of a mixed formulation of conventional and PEGylated liposomes containing meglumine antimoniate, combined with allopurinol, in dogs naturally infected with Leishmania infantum
10.1128/aac.00234-20 · 2020 · External reference
Liposomal amphotericin B for treatment of leishmaniasis: from the identification of critical physicochemical attributes to the design of effective topical and oral formulations
10.3390/pharmaceutics15010099 · 2023 · External reference
Biodistribution and tissue toxicity of amphotericin B in mice following multiple dose administration of a novel oral lipid-based formulation (ICo-009)
10.1093/jac/dkq358 · 2010 · External reference
10.1093/jac/dkag110
10.1093/jac/dkag110 · External reference
Safety, tolerability, and pharmacokinetics of a novel oral amphotericin B formulation (ICo-019) following single-dose administration to healthy human subjects: an alternative approach to parenteral amphotericin B administration
10.1128/aac.01450-20 · 2020 · External reference
Preclinical assessment of ursolic acid loaded into nanostructured lipid carriers in experimental visceral leishmaniasis
10.3390/pharmaceutics13060908 · 2021 · External reference
Amphotericin B: a drug of choice for visceral leishmaniasis
10.1016/j.actatropica.2022.106661 · 2022 · External reference
Recent advances in amphotericin B delivery strategies for the treatment of leishmaniases
10.1080/17425247.2019.1659243 · 2019 · External reference
Cochleate formulations of amphotericin B designed for oral administration using a naturally occurring phospholipid
10.1016/j.ijpharm.2021.120688 · 2021 · External reference
Pharmacokinetics, biodistribution, and activity of amphotericin B-loaded nanocochleates on the Leishmania donovani murine visceral leishmaniasis model
10.1016/j.ijpharm.2022.121985 · 2022 · External reference
Mice with a selective impairment of IFN-γ signaling in macrophage lineage cells demonstrate the critical role of IFN-γ-activated macrophages for the control of protozoan parasitic infections in vivo
10.4049/jimmunol.0902346 · 2010 · External reference
Stability and transdermal absorption of topical amphotericin B liposome formulations
10.1016/j.ijpharm.2003.10.031 · 2004 · External reference
Distearoyl phosphatidylglycerol and dioleoyl phosphatidylglycerol increase the retention and reduce the toxicity of amphotericin B-loaded nanoemulsions
10.2217/nnm-2023-0256 · 2024 · External reference
Mechanisms of resistance and susceptibility to experimental visceral leishmaniosis: BALB/c mouse versus syrian hamster model
10.1186/1297-9716-42-39 · 2011 · External reference
Gaussian deconvolution: a useful method for form-free modeling of scattering data from mono- and multilayered planar systems
10.1107/s002188981204191x · 2012 · External reference
Growth factor and Th2 cytokine signaling pathways converge at STAT6 to promote arginase expression in progressive experimental visceral leishmaniasis
10.1371/journal.ppat.1004165 · 2014 · External reference
Unresolved reference
2022 · External reference
Unresolved reference
External reference
Formulation of amphotericin B in PEGylated liposomes for improved treatment of cutaneous leishmaniasis by parenteral and oral routes
10.3390/pharmaceutics14050989 · 2022 · External reference
Mixed formulation of conventional and pegylated meglumine antimoniate-containing liposomes reduces inflammatory process and parasite burden in Leishmania infantum-infected BALB/c mice
10.1128/aac.00962-17 · 2017 · External reference
Development of real-time PCR assays for evaluation of immune response and parasite load in golden hamster (Mesocricetus auratus) infected by Leishmania (Viannia) braziliensis
10.1186/s13071-016-1647-6 · 2016 · External reference
How to master the host immune system? Leishmania parasites have the solutions!
10.1093/intimm/dxx075 · 2018 · External reference
Long-circulating liposomes codelivering amphotericin B and retinoic acid for cutaneous leishmaniasis treatment
10.1021/acsomega.5c06156 · 2025 · External reference
Development of mannose-anchored thiolated amphotericin B nanocarriers for treatment of visceral leishmaniasis
10.2217/nnm-2016-0325 · 2017 · External reference
Phase I EnACT trial of the safety and tolerability of a novel oral formulation of amphotericin B
10.1128/aac.00838-20 · 2020 · External reference
Development of a flow-through USP 4 apparatus drug release assay for the evaluation of amphotericin B liposome
10.1016/j.ejpb.2018.11.010 · 2019 · External reference
High-performance liquid chromatographic analysis of amphotericin B in plasma, blood, urine and tissues for pharmacokinetic and tissue distribution studies
10.1016/0378-4347(92)80390-c · 1992 · External reference
Highly effective oral amphotericin B formulation against murine visceral leishmaniasis
10.1086/600105 · 2009 · External reference
A novel tropically stable oral amphotericin B formulation (iCo-010) exhibits efficacy against visceral leishmaniasis in a murine model
10.1371/journal.pntd.0000913 · 2010 · External reference
Review of novel oral amphotericin B formulations for the treatment of parasitic infections
10.3390/pharmaceutics14112316 · 2022 · External reference
Insights into composition–structure–function relationships of Doxil® gained from high-sensitivity differential scanning calorimetry
10.1016/j.ejpb.2016.04.011 · 2016 · External reference
Unresolved reference
External reference
Unresolved reference
External reference
Unresolved reference
External reference
Potential lipid-based strategies of amphotericin B designed for oral administration in clinical application
10.1080/10717544.2022.2161671 · 2023 · External reference
High-performance liquid chromatographic analysis of amphotericin B in plasma, blood, urine and tissues for pharmacokinetic and tissue distribution studies
10.1016/0378-4347(92)80390-c · ExternalCitation · doi-reference
Amphotericin B: a drug of choice for visceral leishmaniasis
10.1016/j.actatropica.2022.106661 · ExternalCitation · doi-reference
In vivo antileishmanial activity and histopathological evaluation in Leishmania infantum infected hamsters after treatment with a furoxan derivative
10.1016/j.biopha.2017.08.096 · ExternalCitation · doi-reference
Insights into composition–structure–function relationships of Doxil® gained from high-sensitivity differential scanning calorimetry
10.1016/j.ejpb.2016.04.011 · ExternalCitation · doi-reference
Development of a flow-through USP 4 apparatus drug release assay for the evaluation of amphotericin B liposome
10.1016/j.ejpb.2018.11.010 · ExternalCitation · doi-reference
Stability and transdermal absorption of topical amphotericin B liposome formulations
10.1016/j.ijpharm.2003.10.031 · ExternalCitation · doi-reference
Cochleate formulations of amphotericin B designed for oral administration using a naturally occurring phospholipid
10.1016/j.ijpharm.2021.120688 · ExternalCitation · doi-reference
Pharmacokinetics, biodistribution, and activity of amphotericin B-loaded nanocochleates on the Leishmania donovani murine visceral leishmaniasis model
10.1016/j.ijpharm.2022.121985 · ExternalCitation · doi-reference
Long-circulating liposomes codelivering amphotericin B and retinoic acid for cutaneous leishmaniasis treatment
10.1021/acsomega.5c06156 · ExternalCitation · doi-reference
Potential lipid-based strategies of amphotericin B designed for oral administration in clinical application
10.1080/10717544.2022.2161671 · ExternalCitation · doi-reference
Recent advances in amphotericin B delivery strategies for the treatment of leishmaniases
10.1080/17425247.2019.1659243 · ExternalCitation · doi-reference
Highly effective oral amphotericin B formulation against murine visceral leishmaniasis
10.1086/600105 · ExternalCitation · doi-reference
How to master the host immune system? Leishmania parasites have the solutions!
10.1093/intimm/dxx075 · ExternalCitation · doi-reference
10.1093/jac/dkag110
10.1093/jac/dkag110 · ExternalCitation · doi-reference
Biodistribution and tissue toxicity of amphotericin B in mice following multiple dose administration of a novel oral lipid-based formulation (ICo-009)
10.1093/jac/dkq358 · ExternalCitation · doi-reference
Gaussian deconvolution: a useful method for form-free modeling of scattering data from mono- and multilayered planar systems
10.1107/s002188981204191x · ExternalCitation · doi-reference
Therapeutic efficacy of a mixed formulation of conventional and PEGylated liposomes containing meglumine antimoniate, combined with allopurinol, in dogs naturally infected with Leishmania infantum
10.1128/aac.00234-20 · ExternalCitation · doi-reference
Phase I EnACT trial of the safety and tolerability of a novel oral formulation of amphotericin B
10.1128/aac.00838-20 · ExternalCitation · doi-reference
Mixed formulation of conventional and pegylated meglumine antimoniate-containing liposomes reduces inflammatory process and parasite burden in Leishmania infantum-infected BALB/c mice
10.1128/aac.00962-17 · ExternalCitation · doi-reference
Safety, tolerability, and pharmacokinetics of a novel oral amphotericin B formulation (ICo-019) following single-dose administration to healthy human subjects: an alternative approach to parenteral amphotericin B administration
10.1128/aac.01450-20 · ExternalCitation · doi-reference
Pharmacokinetics, excretion, and mass balance of liposomal amphotericin B (AmBisome) and amphotericin B deoxycholate in humans
10.1128/aac.46.3.828-833.2002 · ExternalCitation · doi-reference
Mechanisms of resistance and susceptibility to experimental visceral leishmaniosis: BALB/c mouse versus syrian hamster model
10.1186/1297-9716-42-39 · ExternalCitation · doi-reference
Experience of research nurses with oral encochleated amphotericin B for treatment of cryptococcal meningitis in a resource-limited setting
10.1186/s12879-025-11319-1 · ExternalCitation · doi-reference
Development of real-time PCR assays for evaluation of immune response and parasite load in golden hamster (Mesocricetus auratus) infected by Leishmania (Viannia) braziliensis
10.1186/s13071-016-1647-6 · ExternalCitation · doi-reference
A novel tropically stable oral amphotericin B formulation (iCo-010) exhibits efficacy against visceral leishmaniasis in a murine model
10.1371/journal.pntd.0000913 · ExternalCitation · doi-reference
Growth factor and Th2 cytokine signaling pathways converge at STAT6 to promote arginase expression in progressive experimental visceral leishmaniasis
10.1371/journal.ppat.1004165 · ExternalCitation · doi-reference
Mixed formulation of conventional and pegylated liposomes as a novel drug delivery strategy for improved treatment of visceral leishmaniasis
10.1517/17425247.2014.932347 · ExternalCitation · doi-reference
Development of mannose-anchored thiolated amphotericin B nanocarriers for treatment of visceral leishmaniasis
10.2217/nnm-2016-0325 · ExternalCitation · doi-reference
Distearoyl phosphatidylglycerol and dioleoyl phosphatidylglycerol increase the retention and reduce the toxicity of amphotericin B-loaded nanoemulsions
10.2217/nnm-2023-0256 · ExternalCitation · doi-reference
Development, characterization, efficacy and mode of action of Ambisome, a unilamellar liposomal formulation of amphotericin B
10.3109/08982109309150729 · ExternalCitation · doi-reference
Preclinical assessment of ursolic acid loaded into nanostructured lipid carriers in experimental visceral leishmaniasis
10.3390/pharmaceutics13060908 · ExternalCitation · doi-reference
Formulation of amphotericin B in PEGylated liposomes for improved treatment of cutaneous leishmaniasis by parenteral and oral routes
10.3390/pharmaceutics14050989 · ExternalCitation · doi-reference
Review of novel oral amphotericin B formulations for the treatment of parasitic infections
10.3390/pharmaceutics14112316 · ExternalCitation · doi-reference
Liposomal amphotericin B for treatment of leishmaniasis: from the identification of critical physicochemical attributes to the design of effective topical and oral formulations
10.3390/pharmaceutics15010099 · ExternalCitation · doi-reference
Mice with a selective impairment of IFN-γ signaling in macrophage lineage cells demonstrate the critical role of IFN-γ-activated macrophages for the control of protozoan parasitic infections in vivo
10.4049/jimmunol.0902346 · ExternalCitation · doi-reference
Natural resistance of Leishmania infantum to Miltefosine contributes to the low efficacy in the treatment of visceral Leishmaniasis in Brazil
10.4269/ajtmh.18-0949 · ExternalCitation · doi-reference
